Maravai LifeSciences Holdings, Inc. (MRVI) News
Follow Maravai LifeSciences Holdings, Inc. (MRVI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
MRVI Q3 Revenue Rises, Net Loss Narrows; Price Target Raised to $9
EQUITY | Nov 06, 2026, 08:05 AM UTC
L
Maravai LifeSciences 3Q 2026: Revenue $45.85M — 10-Q Summary
Maravai LifeSciences’ third-quarter revenue rose year over year, while its net loss narrowed. Higher TriLink demand for research-use raw materials, Discovery mRNA and GMP consumables, along with CDMO strength and increas
EARNINGS | Nov 05, 2026, 09:18 PM UTC
M
Maravai LifeSciences Provides FY Revenue Outlook
Maravai LifeSciences' FY revenue outlook is above the IBES estimate.
EARNINGS | Nov 04, 2026, 09:06 PM UTC
M
Maravai LifeSciences Q3 Revenue Reaches $45.9 Million
Q3 adjusted EBITDA was $5.8 million, versus the IBES estimate of $512.9 thousand.
EQUITY | Nov 04, 2026, 09:03 PM UTC
M
Maravai LifeSciences Reports Third-Quarter 2026 Results
Third-quarter total revenue rose 10% year over year, while mRNA revenue increased 28%.
EQUITY | Nov 04, 2026, 09:02 PM UTC
M
Maravai LifeSciences Reports Q2 Revenue Growth, Raises EBITDA Guidance
Maravai reported Q2 2026 revenue of $51.4 million, up 9% year over year, and adjusted EBITDA of $8.7 million. It maintained 2026 revenue guidance at $205 million to $215 million and raised adjusted EBITDA guidance to $33
EQUITY | Oct 13, 2026, 08:58 AM UTC
L
Maravai LifeSciences: Adds Composition-of-Matter Protection to Reinforce Global IP
Maravai LifeSciences: Adds Composition-of-Matter Protection to Reinforce Global IP
NEWS | Sep 29, 2026, 08:06 PM UTC
L
Maravai LifeSciences: New Patent Extends Beyond Method Claims to Cover the Molecules at the Heart of Modern mRNA Medicines >MRVI
Maravai LifeSciences: New Patent Extends Beyond Method Claims to Cover the Molecules at the Heart of Modern mRNA Medicines >MRVI
NEWS | Sep 29, 2026, 08:06 PM UTC
L
Maravai LifeSciences: TriLink BioTechnologies Secures Additional China Patent for CleanCap Technology
Maravai LifeSciences: TriLink BioTechnologies Secures Additional China Patent for CleanCap Technology
GEOPOLITICS | Sep 29, 2026, 08:05 PM UTC
L
Maravai LifeSciences: New Patent Protects the CleanCap Cap Analog Compounds Themselves and mRNA-Based Pharmaceutical Compositions >MRVI
Maravai LifeSciences: New Patent Protects the CleanCap Cap Analog Compounds Themselves and mRNA-Based Pharmaceutical Compositions >MRVI
NEWS | Sep 29, 2026, 08:05 PM UTC
L
Maravai LifeSciences (MRVI) Secures Second China CleanCap Patent Covering Cap Analogs
Maravai LifeSciences said TriLink BioTechnologies received a second China CleanCap patent, adding composition-of-matter protection for cap analogs and related RNA, cells, and pharma compositions.Material DetailsContext b
GEOPOLITICS | Sep 29, 2026, 08:01 PM UTC
L
TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP
TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ:MRVI) and global provider of life science reagents and services, today announced it has been granted a new patent from the China National In
GEOPOLITICS | Sep 29, 2026, 08:01 PM UTC
L
MRVI maintained at neutral by UBS
UBS maintained Maravai LifeSciences at neutral on MRVI.
EQUITY | Sep 09, 2026, 06:02 PM UTC
M
Merck and Moderna report interim Phase 3 vaccine data hits endpoint
Merck and Moderna said interim Phase 3 data for Moderna’s personalized cancer vaccine met its primary endpoint, with Wells noting potential beneficiaries include RGEN, DHR, TMO and MRVI.
EQUITY | Aug 20, 2026, 01:25 PM UTC
L
MRVI Positive mRNA Cancer Vaccine Readout - Increases Visibility for Entire Life Science Sector and MRVI @ KEYB
MRVI Positive mRNA Cancer Vaccine Readout - Increases Visibility for Entire Life Science Sector and MRVI @ KEYB
EQUITY | Aug 20, 2026, 11:01 AM UTC
L
Maravai LifeSciences Affirms FY2026 Sales Guidance of $205.000M-$215.000M vs $210.433M Est
Maravai LifeSciences (NASDAQ: MRVI ) affirms FY2026 sales outlook from $205.000 million-$215.000 million to $205.000 million-$215.000 million vs $210.433 million estimate.
EARNINGS | Aug 06, 2026, 08:12 PM UTC
L
MRVI Maravai unit TriLink wins China patent for CleanCap mRNA capping technology Maravai LifeSciences’ TriLink unit secured a newly issued C
MRVI Maravai unit TriLink wins China patent for CleanCap mRNA capping technology Maravai LifeSciences’ TriLink unit secured a newly issued China patent for CleanCap mRNA capping technology, strengthening IP Protection in
GEOPOLITICS | Jul 20, 2026, 08:06 PM UTC